1. Home
  2. RLMD vs DIN Comparison

RLMD vs DIN Comparison

Compare RLMD & DIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

SELL

Current Price

$3.06

Market Cap

348.8M

Sector

Health Care

ML Signal

SELL

Logo Dine Brands Global Inc.

DIN

Dine Brands Global Inc.

SELL

Current Price

$37.22

Market Cap

378.8M

ML Signal

SELL

Company Overview

Basic Information
Metric
RLMD
DIN
Founded
2004
1958
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
348.8M
378.8M
IPO Year
2012
1994

Fundamental Metrics

Financial Performance
Metric
RLMD
DIN
Price
$3.06
$37.22
Analyst Decision
Strong Buy
Hold
Analyst Count
4
6
Target Price
$10.75
★ $35.67
AVG Volume (30 Days)
★ 1.7M
566.8K
Earning Date
11-12-2026
11-04-2026
Dividend Yield
N/A
★ 2.05%
EPS Growth
★ 45.28
N/A
EPS
N/A
★ 1.29
Revenue
$13,070.00
★ $879,300,000.00
Revenue This Year
N/A
$11.39
Revenue Next Year
N/A
$2.63
P/E Ratio
★ N/A
$28.75
Revenue Growth
★ 154.83
8.25
52 Week Low
$3.07
$24.46
52 Week High
$8.00
$39.68

Technical Indicators

Market Signals
Indicator
RLMD
DIN
Relative Strength Index (RSI) 37.32 65.15
Support Level N/A $33.10
Resistance Level $3.55 N/A
Average True Range (ATR) 0.43 1.54
MACD -0.04 0.03
Stochastic Oscillator 4.05 86.70

Price Performance

Historical Comparison
RLMD
DIN

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

About DIN Dine Brands Global Inc.

Dine Brands Global Inc owns and franchises thousands of restaurants under the International House of Pancakes (IHOP), Applebee's Neighborhood Grill + Bar (Applebee's), and the Fuzzy's Taco Shop (Fuzzy's) names. The company conducts its business through three reportable segments: Franchise, Company-owned restaurants, and Rental. The majority of its revenue is generated from the Franchise segment, which consists of IHOP, Applebee's, and Fuzzy's franchise operations and generates revenue mainly from royalties and advertising fees from several IHOP, Applebee's, and Fuzzy's franchised restaurants, in addition to revenues from the sale of proprietary IHOP and Fuzzy's products to its franchisees. Geographically, the majority of the company's revenues is generated from its domestic market.

Share on Social Networks: